Introduction
Atherosclerotic occlusive disease involving the iliac arteries is a common cause of intermittent claudication and may also contribute to critical limb ischemia (CLI) symptoms. For many years, an endovascular-first approach has been recommended for relatively simple iliac artery disease, 1 but endovascular treatment is now proving to be a viable alternative to surgical revascularization for more challenging iliac disease. [2] [3] [4] Stents are frequently used for iliac artery revascularization and have frequently demonstrated improved patency 5 and durability 6 over balloon angioplasty, especially in the common iliac arteries (CIAs). Covered stents have been traditionally used to treat conditions involving arterial wall disruption, including iatrogenic and external trauma. 7 Recently, covered stents have been evaluated in aortoiliac occlusive disease, where they may provide a patency advantage over bare metal stents, particularly in aortic bifurcation disease.
describes the first-in-human iliac artery experience of a new BE stent-graft that combines the advantages of a high radial strength BE stent with the deliverability and conformability of a SE endoprosthesis.
Methods

Study Design
This was a prospective, single-center, nonrandomized, single-arm, first-in-human clinical study evaluating the safety and early efficacy of a BE covered endoprosthesis (W.L. Gore & Associates, Inc, Flagstaff, AZ, USA; referred to as the "study device") for the treatment of arterial occlusive disease in symptomatic patients with de novo or restenotic lesions in the CIA and/or external iliac arteries (EIA). Institutional review board and national ethics committee approval were obtained prior to commencing the study. An independent Data and Safety Monitoring Board and Clinical Events Committee provided oversight. Enrolled patients will be followed through 3 years. The angiographic and duplex ultrasound findings were site reported for this 12-month analysis.
Study Device
The Gore BE covered endoprosthesis consists of a stainless steel stent and a fluoropolymer graft ( Figure 1A ). The stent is made up of discrete fluoropolymer-connected stainless steel rings that provide high radial strength, excellent radiopacity, flexibility, conformability, trackability, and minimal foreshortening. The stent is fully encapsulated in the fluoropolymer, and the endoprosthesis is coated with the CARMEDA BioActive Heparin Surface consisting of stable, covalent, reduced-molecular-weight heparin of porcine origin designed to resist thrombus formation. The endoprosthesis is premounted on a 0.035-inch guidewire-compatible delivery system equipped with a fluoropolymer-/ elastomer-covered balloon designed to enhance device retention during delivery ( Figure 1B ). For this study, the endoprosthesis was available in lengths of 15 to 59 mm (Table 1 ) mounted on 80-or 135-cm-long catheters. The labeled device diameter ranged between 5 and 10 mm, but the devices could be postdilated up to 4 mm larger. A compliance chart was provided to calculate internal diameter after the recoil typical of BE stents, which is minimal with the Gore device.
Inclusion/Exclusion Criteria
Patients were eligible for the study if they had claudication or rest pain (Rutherford categories 2-4) and angiographic confirmation of de novo or restenotic occlusive lesions in CIAs or EIAs measuring between 5 and 13 mm in diameter. Each stenotic lesion was defined as ≥50% diameter loss by visual estimate. Kissing stent treatment at the aortic bifurcation was permitted. Up to 2 discrete lesions could be treated per patient with up to 3 study devices for a maximum treated length ≤110 mm.
Patients with a stent or stent-graft within 5 mm of the target lesion were excluded. Other angiographic exclusion criteria included visible thrombus in the target lesion, aneurysmal dilatation adjacent to the target lesion that would interfere with stent placement, and a lesion close to the iliac artery bifurcation that would result in impaired internal iliac artery perfusion. Lesions requiring atherectomy or any ablative device to facilitate stent delivery were also excluded. Important clinical exclusion criteria included severe chronic renal insufficiency (serum creatinine >2.5 mg/dL), uncorrected bleeding disorder (platelet count <80,000/µL), or previous or planned bypass surgery in the target limb. 
Subject Screening
All patients were initially screened with contrast-enhanced magnetic resonance angiography following standard institutional guidelines. Patients with arterial anatomy suitable for the trial were then assessed for compliance with the inclusion and exclusion criteria. Eligible patients provided informed consent and then underwent preprocedure evaluation, including medical history and examination, Rutherford category assessment, resting ankle-brachial index (ABI) measurement, blood analysis, and Walking Impairment Questionnaire (WIQ). Long-term aspirin therapy (100 mg/d) was begun if not already in place. Patients were enrolled when the study device was delivered to the target lesion.
Study Procedure
During the index procedure, single or bilateral percutaneous retrograde common femoral artery access was obtained.
Patients were given a 300-mg loading dose of clopidogrel on the day of the procedure. Heparin was administered to maintain an activated clotting time ≥225 seconds. Radiopaque calibrated marker tape was used. Once angiographic confirmation of anatomical suitability was obtained, the target lesion was either predilated with a plain angioplasty balloon or primarily treated with the study device at the operator's discretion. The study device was deployed to achieve a size ratio of 1:1 or 1.1:1 compared with the adjacent healthy vessel following the pressure-diameter compliance chart provided with the device. Percutaneous closure devices were permitted. Patients were discharged on lifelong aspirin and clopidogrel (75 mg/d) for at least 9 months. Follow-up in the vascular clinic was scheduled at 1, 6, and 12 months and annually to 3 years. At each visit, clinical examination, Rutherford category assessment, ABI measurement, and duplex ultrasound were performed. The WIQ was administered at each encounter. Unscheduled clinic visits and reinterventions were documented, as were adverse events.
Patient Population
Thirty patients (mean age 64 years; 18 men) with 43 iliac artery lesions were recruited to this trial, with the last patient enrolled in December 2015. Of the 43 lesions treated, 39 (91%) were stenoses (Figure 2A and B) and 4 were occlusions ( Figure 2C and D); 14 lesions were located in the EIA. Mean lesion length was 31.6 mm, and 6 lesions exhibited moderate to severe calcification ( Figure 3) . The majority of patients were Rutherford 3 claudicants (n=24) with the usual risk factors for atherosclerosis (Table 2) ; TASC (TransAtlantic Inter-Society Consensus) class C lesions predominated.
Endpoints and Outcome Measures
The primary safety endpoint was a composite of device-or procedure-related death, myocardial infarction (MI), or amputation above the metatarsals in the treated leg resulting from a vascular event within 30 days of the index procedure.
The secondary outcome measures were acute procedure success [≤30% residual stenosis on completion angiography without a device-or procedure-related major adverse event (MAE) before discharge]; 30-day clinical success (improvement of at least 1 Rutherford category and no MAE); primary, assisted primary, and secondary patency rates; freedom from target lesion revascularization (TLR); freedom from target vessel revascularization (TVR); freedom from MAE (no device-or procedure-related death or MI within 30 days and no TLR or major limb amputation within 6 months); and changes in Rutherford category, ABI, and WIQ at all time points to 12 months. 
Statistical Analysis
Analysis was performed on all evaluable subjects (intentto-treat). The Kaplan-Meier method was used to estimate patency and freedom from TLR, TVR, and MAE at 1, 6, and 12 months. Changes in ABI from baseline to 12-month follow-up were evaluated for significance using a paired t test. The threshold of statistical significance was p<0.05. Analyses were performed using SAS software (version 9.3; SAS Institute, Inc, Cary, NC, USA).
Results
A total of 49 study devices were implanted without failure in delivery or deployment. Predilation of the target lesion was performed with plain balloon angioplasty in 5 (17%) patients. In 8 (27%) patients, a target lesion was treated from the contralateral femoral artery approach (Figure 4 ). Mean stented length was 50.1 mm. Ten patients received kissing stents at the aortic bifurcation. Acute procedure success was achieved in 100% of patients, with no >30% residual stenosis or MAE before hospital discharge.
As is frequently seen with covered endoprostheses, the blood lumen within the study device was not always well visualized on duplex ultrasound performed within 24 hours, possibly due to entrapped air providing acoustic shadowing. However, on subsequent duplex ultrasound studies, the study device and blood lumen were well seen ( Figure 5 ).
The 30-day primary safety endpoint was 0%. Thirty-day clinical success was achieved in 28 (93%) patients; 2 did not experience an improvement in Rutherford category despite successful iliac artery revascularization. Both patients had ipsilateral superficial femoral artery (SFA) occlusive disease and underwent successful SFA intervention >30 days after the index procedure, with symptom improvement. Twelve-month data were available on 29 patients; 1 patient expired at 6 months due to acute MI not deemed procedure-or device-related. Kaplan-Meier estimates of per-subject primary patency, freedom from TLR, and freedom from TVR were 100% at 1 and 6 months and 96.6% at 12 months ( Figure 6 ). One patient with bilateral CIA study devices experienced recurrent symptoms referable to left CIA stent edge restenosis at 7 months; the lesion was successfully managed with angioplasty and stenting ( Figure 7) . The remaining treated segments were patent at 12 months, including all segments in the EIA (CIA and EIA primary patency estimates were 93.1% and 100.0%, respectively). Assisted primary and secondary patency estimates were 100% at 12 months. The freedom from MAE was 100%.
Most patients experienced a sustained improvement in Rutherford category over 12 months, with 50% of patients having no claudication symptoms at 1 year ( Figure 8A ). The resting ABI was also improved from a mean 0.79 preprocedure to 0.95 at 12 months (p<0.001). Patient functional status was also improved as measured by the WIQ ( Figure 8B ).
Discussion
Endovascular treatment of TASC A and B iliac artery disease has been the preferred management strategy for many years, 1 and there is increasing evidence that endovascular techniques offer a viable alternative to surgical revascularization for more challenging TASC C and D iliac disease. [2] [3] [4] Published analyses of iliac stents have reported low rates of adverse events and TLR, especially in the first 2 years posttreatment. 10, 11 The choice of stent in the iliac segment is influenced by the characteristics of the stent as well as vessel and lesion characteristics. 12 A wide variety of SE and balloon-mounted bare metal stents are available. Given their high radial strength, BE stents tend to be used for CIA steno-occlusive disease, including lesions at the aortic bifurcation. SE stents may be used in the EIA, a vessel more likely to undergo deformity with hip movement. The BRAVISSIMO trial, a prospective multicenter monitored registry included 325 patients with aortoiliac occlusive disease. 13 Interestingly, this study involved significantly more BE stents used in TASC A and B lesions, while significantly more SE stents were used in TASC C and D lesions. The kissing stent configuration for aortic bifurcation reconstruction and patient obesity were the only predictors of restenosis (primary patency failure) based on univariate and multivariable regression analyses. Neither lesion length nor TASC category was predictive of restenosis. Covered stents have traditionally been reserved for situations in which the arterial wall is disrupted, including iatrogenic trauma following angioplasty or the introduction of large caliber endovascular devices, pelvic trauma, or mycotic aneurysm. 7 Recently, both SE 14 and BE covered stents have been evaluated in aortoiliac occlusive disease to see if there is a patency advantage over bare metal stents. The COBEST trial randomized 168 iliac arteries in 125 patients to receive either covered BE or bare metal (either BE or SE) stents. 15 The investigators demonstrated that the patients with TASC C and D lesions treated with covered stents were more likely to remain free from binary restenosis than those treated with bare metal stents. No distinction was made between the treatment of CIA or EIA lesions, so no firm conclusions can be drawn about the different stent behaviors in these vessels. 16 A prospectively enrolled but nonrandomized registry including 167 iliac arteries stented in 128 patients (51% bare metal stents, 49% covered stents) demonstrated comparable outcomes of covered and bare metal stents in TASC C and D lesions. 17 However, increased primary patency was seen with covered stents in a subgroup of TASC D lesions with long segment stenotic disease involving the CIA/EIA. Others have reported improved patency for uncovered BE stents over covered stents in the CIA. 18 Endovascular management of occlusive disease at the aortic bifurcation may be challenging. Atherosclerotic plaque is often calcified and resistant to angioplasty, and the caliber change and angulation between the aorta and the CIAs may be problematic. The use of kissing stents (both SE and BE) has been shown to provide excellent acute reconstruction in aortic bifurcation disease, 19, 20 although the long-term patency is less impressive. 21 Covered endovascular stent reconstruction of the aortic bifurcation (CERAB) has been proposed to improve long-term patency at this site. An in vitro study using anatomical vessel phantoms found CERAB to have the lowest radial mismatch compared to SE and BE stents, suggesting CERAB represents the best anatomical and physiological reconstruction of the aortic bifurcation. 22 Early clinical experience with CERAB is promising. [23] [24] [25] Both BE and SE covered stents have been used in the iliac arteries. BE covered stents have been most frequently used and have the high radial strength and placement accuracy provided by a BE platform. However, they are relatively rigid, which can inhibit trackability and deliverability, especially over the aortic bifurcation. SE covered stents are more flexible but lack high radial outward force. The Gore BE covered endoprosthesis has been developed to optimize the positive features of a BE covered stent while being deliverable and compliant. The discrete stainless steel rings provide high radial resistive force with minimal foreshortening and excellent radiopacity. The fluoropolymer connections afford the flexibility, conformability, and trackability usually associated with a SE stent. Full encapsulation of the stent with fluoropolymer is important. The outer layer optimizes apposition to the vessel wall while the inner layer provides a smooth luminal surface that facilitates guidewire access should recanalization be necessary. The CARMEDA BioActive Heparin Surface coating provides thrombus resistance.
All BE stents recoil after deployment. Although this is minimal with the Gore device, a compliance chart is included that accurately calculates the post-recoil stent internal diameter. This is a particularly useful reference for optimizing stent apposition and lumen diameter.
In this first-in-human experience with the Gore BE covered stent, a range of iliac occlusive lesions were included, including over a quarter treated across the aortic bifurcation. The ability to reliably deliver a BE covered stent via a contralateral groin approach represents a significant advantage.
The device conformed well to the vessel, including points of tortuosity. Predilation was required in a minority of cases, minimizing the risk of arterial rupture or distal embolization. Procedure safety was excellent, as was the 97% 12-month primary patency. To put this in context, reported 12-month patency rates range from 86% to 87% 9, 20, 26 for bare metal stents and from 87% to 89% for covered stents. 25, 27 This excellent result was achieved despite the patient cohort representing a "real world" selection of anatomies with no exclusion criteria regarding iliac tortuosity, severe calcification, or the use of reentry devices.
Conclusion
The positive first-in-human experience with the Gore BE covered endoprosthesis suggests this device will have an important role in the management of aortoiliac occlusive disease. Further experience in the iliac arteries as well as other anatomical locations is anticipated.
